BD and Biodiversity collaborate on infection tests for transplant patients
This article was originally published in Clinica
Privately-held Italian biotech firm Biodiversity is teaming up with BD Diagnostics to develop and commercialise a menu of molecular diagnostics for immunocompromised patients which will run on the BD Max system. Biodiversity will develop the tests, which will be designed to improve the monitoring of infections in transplant recipients who are at high risk because of the immunosuppressant drugs needed to prevent transplant rejection. The assays produced through the collaboration are intended to be CE marked for sale in Europe initially – this could later be expanded to include approval in other countries and regions, according to the companies. BD Diagnostics, part of Becton Dickinson, is currently expanding the menu for its automated BD Max system, and there are currently 15 tests in the pipeline. Earlier this month, the company agreed to develop a BD Max test for Aspergillus infection with personalised medicine specialist Lab21.